⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Xelalix and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Xelalix
↗Basel, Switzerland
Xelalix is a biotechnology company headquartered in Basel, Switzerland, that leverages advanced Artificial Intelligence (AI) and machine learning to revolutionize the drug discovery process. The company focuses on accelerating the identification and optimization of novel therapeutic candidates, particularly for targets that have been historically difficult to drug.
By integrating deep domain expertise in medicinal chemistry with cutting-edge computational platforms, Xelalix aims to reduce the time and cost associated with early-stage drug development. The company operates at the intersection of technology and biology, positioning itself as a next-generation 'tech-bio' player in the European ecosystem.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue
Founded:2023
Ownership:private
Status:operating
FUNDING
Stage:Seed
Investors:Undisclosed Angel Investors, Venture Incubators (Switzerland)
PIPELINE
Stage:Discovery
Lead Drug Stage:Discovery/Target Validation
Modalities:Small molecule, Computational design
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Academic collaborations in Basel biotech hub
COMPETITION
Position:Emerging
Competitors:Exscientia, Recursion Pharmaceuticals, Insilico Medicine, Schrodinger, Relay Therapeutics
LEADERSHIP
Key Executives:
Jamil El-Ali - Founder & CEO
Scientific Founders:Jamil El-Ali
LINKS
Website:xelalix.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Xelalix. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.